Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Study of MGCD516 in Patients with Advanced Solid Tumors (17038) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Nivolumab in Combination with either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration- Resistant Metastatic Prostate Cancer (17149) II
Mary Beth WIlwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Trial Assessing The Tolerability Of Palbociclib In Combination With Letrozole Or Fulvestrant In Patients Aged 70 And Older With Estrogen Receptor Positive, Her2-Negative Metastatic Breast Cancer (A171601) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Exploratory Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First Line Treatment of Metastatic Colorectal Cancer(17186 CA2099X8) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An International, Open Label, Randomized Trial of Sacituzumab Govitecan vs Treatment of Physician Choice in Patients with Metastatic, Triple Negative Breast Cancer Who Have Received at Least Two Prior Treatments (16023) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open-label Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies 16041 (CA209-267) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open-Label Study of Itacitinib in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis (17085) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer (16010) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (GU002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (S1400) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Blood Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Clinical Trial Evaluating Post- Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After (B51) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Crizotinib vs Placebo for Patients with Tumors Harboring the ALK Fusion Protein (E4512) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Electronic Patient Reporting Of Symptoms During Cancer Treatment (AFT-39) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Integrated Cancer Repository for Cancer Research (iCaRe2) – Breast Cancer Collaborative Repository - BCCR III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Molecular Analysis for Therapy Choice (NCI MATCH) (EAY131) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Multiple Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies(CA209-039) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusThis III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Open Label Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Axitinib in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naïve Cisplatin-Inelgible Urothelial Cancer (B9991027) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Open Label Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Axitinib in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naïve Cisplatin-Inelgible Urothelial Cancer (B9991027) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members